![[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care](https://imgproxy.divecdn.com/5lAJkli_KcGt1FSsw4EaegjgP76IHREqYEWbhNBJOXw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlXzEzNDZfeF83MjlfQXJ0d29yay5qcGc=.webp)
.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Onpattro, patisiran, D...
Extensions of marketing authorisations: questions and answers
The startup is bringing into Phase 1 testing an experimental treatment it says c...
The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZenec...
Human medicines European public assessment report (EPAR): Mvabea, Ebola vaccine ...
Agenda - PDCO agenda of the 25-28 March 2025 meeting
Minutes of the CVMP meeting 11-12 February 2025
EMA multi-stakeholder workshop on reporting and qualification of mechanistic mod...
The arc of biotechnology is one of breakthroughs and struggles, writes Tim Hunt,...
“We’re the richest country in the world. It’s callous to say it’s costing too mu...
Health insurers are using more AI but a lack of transparency makes it difficult ...
Opinion/decision on a Paediatric investigation plan (PIP): Verzenios, abemacicli...
Monarez is the CDC's acting director and a longtime biosecurity expert with ties...
Melbourne Australia | 21 March 2025 -- Telix today announces that the United Sta...
The genetics company's bankruptcy is bad for co-founder Anne Wojcicki and shareh...
Prominent outside scientists who help the NIH evaluate its internal research pro...
The company expects next quarter to read out initial data from its Heart-2 trial...
Monarez is the CDC's acting director and a longtime biosecurity expert with ties...
The DNA-testing company plans to sell its assets after the board rejected an acq...
MONDAY, March 24, 2025 -- For patients with ischemic stroke, tenecteplase seems...